Use of Ceftazidime-Avibactam for Suspected or Confirmed Carbapenem-Resistant Organisms in Children: A Retrospective Study
Open Access
- 1 September 2023
- journal article
- research article
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 16, 5815-5824
Abstract
Background: The incidence of carbapenem-resistant organism (CRO) infections is increasing in children. However, pediatric-specific treatment strategies present unique challenges. Ceftazidime/avibactam is a β-lactam/β-lactamase inhibitor combination, showing adequate efficiency against CRO isolates. However, clinical data on the efficacy of ceftazidime/avibactam in children are still lacking. Methods: This was a retrospective study of children (aged < 18 years) infected with confirmed or suspected carbapenem-resistant pathogens and treated with ceftazidime-avibactam at the First Affiliated Hospital of Zhengzhou University between 2020 and 2022. Results: We identified 38 children aged 14 (5.0– 16.3) years; 20 (52.6%) had hematologic malignancies. 25 children with confirmed CRO infections were administered ceftazidime-avibactam as targeted therapy. The median treatment was 10 (6.0– 16.5) days. Among them, 24 had infections caused by carbapenem-resistant Enterobacterales (CRE) (18 carbapenem-resistant Klebsiella pneumoniae and six carbapenem-resistant Escherichia coli species) and one with carbapenem-resistant Pseudomonas aeruginosa strains. The source of infection was the bloodstream in 60.0% of the cases (15/25). The clinical response rate was 84.0% (21/25), and 30-day mortality rate was 20% (5/25). 13 children were administered ceftazidime-avibactam as empiric therapy for suspected infections. The median treatment was 8 (6.0– 13.0) days. No deaths occurred and clinical response was achieved in 12 of the 13 patients (92.3%) who empirically treated with ceftazidime-avibactam. Conclusion: Ceftazidime-avibactam is important for improving survival, and clinical response in children with infections caused by CRO.Keywords
This publication has 42 references indexed in Scilit:
- Carbapenem-resistant Enterobacteriaceae colonization and infection in critically ill patients: a retrospective matched cohort comparison with non-carriersJournal of Hospital Infection, 2016
- Carbapenem-resistant Enterobacteriaceae Infections in ChildrenThe Pediatric Infectious Disease Journal, 2016
- Metallo-β-Lactamase (MBL)-Producing Enterobacteriaceae in United States ChildrenOpen Forum Infectious Diseases, 2016
- Clinical Characteristics of Carbapenem-resistant Klebsiella pneumoniae Infections in Ill and Colonized Children in ColombiaThe Pediatric Infectious Disease Journal, 2016
- Carbapenem-ResistantEnterobacteriaceaein Children, United States, 1999–2012Emerging Infectious Diseases, 2015
- Incidence of colonization and bloodstream infection with carbapenem-resistant Enterobacteriaceae in children receiving antineoplastic chemotherapy in ItalyInfectious Diseases, 2015
- Pediatric Carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a High-prevalence Region in the United StatesThe Pediatric Infectious Disease Journal, 2015
- Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort studyBMC Infectious Diseases, 2014
- Infections Caused by Carbapenem-resistant Gram-negative Pathogens in Hospitalized ChildrenThe Pediatric Infectious Disease Journal, 2013
- Risk factors for bloodstream infection with Klebsiella pneumoniae producing VIM-1 metallo- -lactamaseJournal of Antimicrobial Chemotherapy, 2010